Last reviewed · How we verify

NCT05244408: SCRIBBLE

"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation

Recruiting now Last updated 3 July 2023
What this trial tests

trial in Acute Spinal Cord Injury in 120 participants. Currently enrolling.

Timeline
17 March 2023
Primary endpoint
30 May 2025
30 May 2026

Quick facts

Lead sponsorUniversity of British Columbia
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date17 March 2023
Primary completion30 May 2025
Estimated completion30 May 2026
Sites1 location across Canada

Conditions studied

Sponsor

University of British Columbia

Who can join

19 and older, any sex, with Acute Spinal Cord Injury or Acute Spinal Paralysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, single center study designed to assess blood biomarkers for classifying injury severity and predict neurologic recovery in traumatic spinal cord injured (SCI) patients. Study will also establish the accuracy of point to care devices for SCI blood biomarkers and support the biospecimen collection for the International Spinal Cord Injury Biobank (ISCIB).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Spinal Cord Injury

Currently open trials in the same condition.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05244408.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing